R&D channel feed – Endpoints News

R&D channel feed

The Ariad vets developing next-gen TKIs are heading back to Nasdaq — and OrbiMed stands to reap the most

4 years ago

Who needs primary endpoints anyway? Aerie touts silver linings from failed PhIIb, plots PhIII in dry eye disease

4 years ago

Zymeworks squares up with Herceptin after HER2 bispecific aces mid-stage test in esophageal cancer

4 years ago

Amgen rolls out data for KRAS inhibitor combo study in colorectal cancer, hoping to move on from ugly early results

4 years ago

Acepodia uncorks a very early win for its antibody-natural killer cell conjugates in HER2 tumors

4 years ago

FDA appears unconvinced by Pfizer's case for Covid-19 booster in lead up to adcomm

4 years ago

FDA clears first-of-its-kind trial to see if CRISPR gene editing can cure HIV

4 years ago

Back-to-back pivotal failures force Theravance to lay off 270 staffers, prune R&D focus

4 years ago

#ESMO21 is looming, and we have a great group of experts lined up to help make sense of the news

4 years ago

Ebola vaccine built on same technology as Covid-19 jab from J&J shows long-lasting success

4 years ago

Fourth boy dies in Astellas-Audentes gene therapy trial, raising fresh fears for the field

4 years ago

Bellus says its Merck cough rival passed a PhIIb test after earlier flop, but investors can't make up their minds

4 years ago

Biden calls on Congress to allow Medicare drug price negotiations

4 years ago

After decade-plus of failures, AstraZeneca finally gets a win for storied immunotherapy (kind of)

4 years ago

Apellis turns up mixed results in closely watched eye disease tests. Are the data strong enough for approval?

4 years ago

Aiming to uproot the market for asthma attacks, AstraZeneca and Avillion tout two PhIII wins for inhaled combo drug

4 years ago

A new clutch of biotech blue-chippers joins Obsidian's quest to craft next-gen drugs with an 'on' switch

4 years ago

Medicxi's mega-startup Centessa rolls out first data for hemophilia drug with plans to charge ahead into pivotal test

4 years ago

Humanigen crashes as FDA shoots down its Covid-19 drug EUA

4 years ago

A top pick in Paul Hudson's campaign to revive the pipeline at Sanofi blows up in PhIII

4 years ago

Top biopharma execs offer scare tactics and mixed messages on drug pricing bills making their way to Capitol Hill

4 years ago

MacroGenics flips over an OS dud for cancer drug Margenza in surprising turnaround from earlier data

4 years ago

Moving on from a major setback, Roche lines up a new Huntington's program for gene therapy sub Spark

4 years ago

As tezepelumab awaits FDA decision, Amgen and AstraZeneca tout more data from the Phase III study

4 years ago

First page Previous page 159 160 161162163 164 165 Next page Last page